Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 13;29(1):5-12.
doi: 10.5606/tgkdc.dergisi.2021.18573. eCollection 2021 Jan.

Endovascular balloon angioplasty for infrainguinal arterial occlusive disease: Efficacy analysis

Affiliations

Endovascular balloon angioplasty for infrainguinal arterial occlusive disease: Efficacy analysis

Mehmet Cahit Sarıcaoğlu et al. Turk Gogus Kalp Damar Cerrahisi Derg. .

Abstract

Background: We present early and mid-term clinical outcomes of endovascular revascularization for femoropopliteal involvement of peripheral arterial disease.

Methods: A total of 128 patients (113 males, 15 females; mean age: 63.4±9.9 years; range, 32 to 87 years) who underwent percutaneous transluminal angioplasty for femoropopliteal lesions between August 2016 and April 2018 were analyzed retrospectively. Treatment with Luminor® paclitaxel-coated drug-eluting balloon catheter or bailout therapy with iVolution® self-expanding nitinol stent were performed. Overall patency rates and freedom from reintervention rates were analyzed using the Kaplan-Meier analysis. The primary patency and freedom from reintervention to target lesion rates at 12 and 24 months were evaluated.

Results: Technical success was achieved in 133 (93%) of the interventions with a median follow-up of 11 (range, 1 to 35) months. At 12 and 24 months, the mean overall patency rates were 85.6±3.7% and 66.8±6.7%, respectively and the mean freedom from reintervention to target lesion rates were 91.6±2.9% and 78.1±6.3%, respectively. The primary patency and freedom from reintervention to target lesion rates were significantly higher in the bailout stenting group than the drug-eluting balloon group at 12 months (97.3±2.7% vs. 94.8±6.1%, respectively, p=0.025 and 97.1±2.9% vs. 84.2±5.5%, respectively, p=0.005) and at 24 months (76.9±7.9% vs. 55.8±13.4%, respectively, p=0.025 and 85.2±7.0% vs. 70.2±13.6%, respectively, p=0.005).

Conclusion: Endovascular procedures including drug-eluting balloon and bailout stenting seem to be effective alternative treatment modalities for treatment of infrainguinal peripheral arterial disease and can be also used in patients with long lesions and/or total occlusion of femoropopliteal arteries.

Keywords: Bail-out therapy; drug-eluting balloon; endovascular procedure; percutaneous transluminal angioplasty; peripheral arterial disease.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

Figures

Figure 1
Figure 1. Primary patency rates of all cohort.
Figure 2
Figure 2. Freedom from reintervention to target lesion rates of all cohort. TL: Target lesion.

Similar articles

References

    1. 2014 "IN. PACT Admiral" Drug-Coated Balloon From Medtronic Outperforms Standard Angioplasty In Landmark Study. Medtronic. News and Information. Available at: http:// newsroom.medtronic.com/phoenix.zhtml?c=251324&p=irolnewsArticle& ID=1916027.
    1. Shammas NW, Abi Doumet A, Karia R, Khalafallah R. An overview of the treatment of symptomatic common femoral artery lesions with a focus on endovascular therapy. Vasc Health Risk Manag. 2020;16:67–73. - PMC - PubMed
    1. Rocha-Singh KJ, Jaff MR, Crabtree TR, Bloch DA, Ansel G, VIVA Physicians Inc Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease. Catheter Cardiovasc Interv. 2007;69:910–919. - PubMed
    1. Davies MG, Anaya-Ayala JE. Endovascular techniques in limb salvage: cutting, cryo, brachy, and drug-eluting balloons. Methodist Debakey Cardiovasc J. 2013;9:69–72. - PMC - PubMed
    1. Werk M, Langner S, Reinkensmeier B, Boettcher HF, Tepe G, Dietz U, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118:1358–1365. - PubMed

LinkOut - more resources